It’s been a year since the gene-editing treatment Casgevy was approved for sickle cell disease and a related blood disorder.

Founded in 1993, The Motley Fool is a financial services company dedicated to making the world smarter, happier, and richer.

Cyclosporin H boosts a new lentivirus-delivered gene therapy with enhanced anti-sickling properties in blood stem cells from ...

McKesson Corporation’s MCK dedicated business focused on supporting the commercialization of cell and gene therapies, ...

Casgevy是全球首款获得监管批准的CRISPR/Cas9基因编辑疗法，其通过CRISPR/Cas9基因编辑系统，在体外对患者自体的造血干细胞进行编辑，使血红细胞生产高水平的胎儿血红蛋白。

It may be possible to collect nearly three times as many stem cells for sickle cell gene therapy with motixafortide than standard plerixafor.

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at ...

Crispr has already secured a historic first approval for a CRISPR/Cas9 drug and has several more potential blockbuster ...

As we commemorate the recent first anniversary of a renowned health journalist who was also a friend, Elizabeth Merab, we ...

A Feature analyzing M&A, licensing and partnerships in gene editing as CRISPR therapeutics enter the market and present new ...